Evgeny Bryun

455 total citations
52 papers, 294 citations indexed

About

Evgeny Bryun is a scholar working on Psychiatry and Mental health, Pharmacology and Pharmacology. According to data from OpenAlex, Evgeny Bryun has authored 52 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Psychiatry and Mental health, 21 papers in Pharmacology and 18 papers in Pharmacology. Recurrent topics in Evgeny Bryun's work include Pharmacogenetics and Drug Metabolism (21 papers), Schizophrenia research and treatment (19 papers) and Treatment of Major Depression (17 papers). Evgeny Bryun is often cited by papers focused on Pharmacogenetics and Drug Metabolism (21 papers), Schizophrenia research and treatment (19 papers) and Treatment of Major Depression (17 papers). Evgeny Bryun collaborates with scholars based in Russia, United States and Germany. Evgeny Bryun's co-authors include Д. А. Сычев, Valentin Yurievich Skryabin, Е. А. Гришина, M. S. Zastrozhin, Smirnov Vv, Kristina Ryzhikova, Михаил Сергеевич Застрожин, Marco Torrado, Dmitrii D. Markov and Stig Tore Bogstrand and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gene and Drug and Alcohol Dependence.

In The Last Decade

Evgeny Bryun

45 papers receiving 284 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Evgeny Bryun Russia	11	94	77	72	57	38	52	294
Hugh Claridge United Kingdom	13	74 0.8×	19 0.2×	92 1.3×	59 1.0×	39 1.0×	20	457
Marion A. Coe United States	7	115 1.2×	26 0.3×	63 0.9×	72 1.3×	7 0.2×	12	393
Christine Goodair United Kingdom	10	74 0.8×	19 0.2×	73 1.0×	67 1.2×	34 0.9×	23	388
Roza Ghotbi Sweden	6	220 2.3×	103 1.3×	142 2.0×	17 0.3×	28 0.7×	6	486
Abbas Ali Nasehi Iran	8	31 0.3×	84 1.1×	86 1.2×	99 1.7×	49 1.3×	12	556
Kristýna Nosková Czechia	8	57 0.6×	35 0.5×	198 2.8×	18 0.3×	31 0.8×	12	316
Joan A. Marshman Canada	11	53 0.6×	31 0.4×	81 1.1×	75 1.3×	67 1.8×	26	381
Jill Chappell United States	8	87 0.9×	94 1.2×	143 2.0×	28 0.5×	6 0.2×	13	396
Anders Lidén Sweden	11	192 2.0×	117 1.5×	68 0.9×	36 0.6×	9 0.2×	14	455
Elizabeth S. Duke United States	10	115 1.2×	145 1.9×	75 1.0×	22 0.4×	7 0.2×	23	666

Countries citing papers authored by Evgeny Bryun

Since Specialization

Citations

This map shows the geographic impact of Evgeny Bryun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evgeny Bryun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evgeny Bryun more than expected).

Fields of papers citing papers by Evgeny Bryun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evgeny Bryun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evgeny Bryun. The network helps show where Evgeny Bryun may publish in the future.

Co-authorship network of co-authors of Evgeny Bryun

This figure shows the co-authorship network connecting the top 25 collaborators of Evgeny Bryun. A scholar is included among the top collaborators of Evgeny Bryun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evgeny Bryun. Evgeny Bryun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zastrozhin, M. S., et al.. (2025). Relationship of the 1846G > A Polymorphism of the CYP2D6 Gene to the Equilibrium Concentration Levels of Haloperidol in Patients with Acute Alcoholic Hallucinosis. Psychopharmacology Bulletin. 53(4). 15–22.

Застрожин, Михаил Сергеевич, et al.. (2025). Influence of CYP2C19*17 Genetic Polymorphism on the Steady-State Concentration of Escitalopram in Patients with Recurrent Depressive Disorder. Psychopharmacology Bulletin. 52(3). 8–19. 2 indexed citations

Zastrozhin, M. S., Valentin Yurievich Skryabin, Е. А. Гришина, et al.. (2025). Impact of the Omics-Based Biomarkers on the Fluvoxamine’s Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology Bulletin. 51(1). 69–80. 1 indexed citations

Bryun, Evgeny, et al.. (2022). Smartphone Medical Apps Use by Health Professionals: Is Gender a Confounding Factor?. Global Journal of Health Science. 14(3). 87–87.

Zastrozhin, M. S., Valentin Yurievich Skryabin, Е. А. Гришина, et al.. (2021). Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders. Journal of Psychiatric Practice. 27(5). 372–379. 6 indexed citations

Zastrozhin, M. S., Valentin Yurievich Skryabin, Marco Torrado, et al.. (2021). Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder. The Pharmacogenomics Journal. 21(4). 435–439. 7 indexed citations

Bryun, Evgeny, et al.. (2020). Prevalence of psychoactive substance use among acutely hospitalised patients in Oslo and Moscow: a cross-sectional, observational study. BMJ Open. 10(9). e032572–e032572. 6 indexed citations

Skryabin, Valentin Yurievich, Михаил Сергеевич Застрожин, Marco Torrado, et al.. (2020). How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?. Drug Metabolism and Personalized Therapy. 0(0). 12 indexed citations

Застрожин, Михаил Сергеевич, Smirnov Vv, Е. А. Гришина, et al.. (2020). The estimation of infl uence of CYP3A activity on the effi cacy and safety of fl uvoxamine in patients with depressive disorders comorbid with alcohol use disorder. 65–75. 1 indexed citations

10.

Застрожин, Михаил Сергеевич, et al.. (2019). <p>Pharmacogenetics of alcohol addiction: current perspectives</p>. The Application of Clinical Genetics. Volume 12. 131–140. 7 indexed citations

11.

Zastrozhin, M. S., et al.. (2018). Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Drug Metabolism and Personalized Therapy. 33(4). 187–194. 6 indexed citations

12.

Zastrozhin, M. S., Е. А. Гришина, Denis O. Lamoureux, et al.. (2018). Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. Human Psychopharmacology Clinical and Experimental. 33(6). e2677–e2677. 17 indexed citations

13.

Zastrozhin, M. S., Е. А. Гришина, Valentin Yurievich Skryabin, et al.. (2018). Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics and Personalized Medicine. Volume 11. 113–119. 18 indexed citations

14.

Bryun, Evgeny, et al.. (2018). Comparative review of the principles and methods of drug treatment applied in Europe and in the Russian Federation. 6(3). 19–39. 1 indexed citations

15.

Bogstrand, Stig Tore, et al.. (2017). The comparative analysis of the methods for the determination of phosphatidylethanol in blood as a biological marker of alcohol abuse. Forensic Medical Expertise. 60(5). 23–23. 3 indexed citations

16.

Сычев, Д. А., M. S. Zastrozhin, Smirnov Vv, et al.. (2017). Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. Drug Metabolism and Personalized Therapy. 32(3). 129–136. 17 indexed citations

17.

Zastrozhin, M. S., V. M. Brodyansky, Valentin Yurievich Skryabin, et al.. (2017). Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. Pharmacogenomics and Personalized Medicine. Volume 10. 209–215. 8 indexed citations

18.

Zastrozhin, M. S., et al.. (2017). The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmacogenomics and Personalized Medicine. Volume 11. 1–5. 10 indexed citations

19.

Сычев, Д. А., et al.. (2016). The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. Pharmacogenomics and Personalized Medicine. Volume 9. 89–95. 18 indexed citations

20.

Davydov, Dmitry M., et al.. (2006). Cognitive deficits and risk of alcohol and drug addictions in attention deficit/hyperactivity disorder. Psikhologicheskii zhurnal. 27(1). 81–88. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact